Re-trying antibody-drug conjugates for advanced breast cancer
Part of Cancer, Skin clinical trials.
This study looks at whether giving a different antibody-drug conjugate (ADC) after a previous one can help people with advanced or metastatic breast cancer. It aims to find new options for patients who have already had ADC treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your breast cancer is advanced or has spread to other parts of the body.
- You have already received at least one type of antibody-drug conjugate (ADC) treatment.
- You have measurable disease (tumors that can be seen on scans).
- You have good organ function (kidneys, liver, heart, and blood counts).
- For hormone receptor-positive breast cancer, you must have taken a CDK4/6 inhibitor before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding famitinib to the drug SHR-A1811 works better than SHR-A1811 alone for people with advanced HR+/HER2- breast cancer that no longer responds to CDK4/6 inhibitors. It is for people with a specific subtype called SNF4, identified by a computer analysis of tumor tissue.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This trial tests a new drug SHR-A2102 combined with other treatments for advanced or metastatic breast cancer. It aims to see if the combination is safe and effective.
This trial tests a combination of two drugs—SHR-A1921 (a targeted therapy) and Adebrelimab (an immunotherapy)—for people with a specific type of advanced breast cancer (HR-positive, HER2-negative, PD-L1 positive). It aims to see if this combo can help when hormone therapy and chemotherapy haven't worked well enough.
This Phase 2 trial tests an investigational “SNF platform” treatment for advanced ER+ (estrogen-receptor positive) and HER2− breast cancer in people who already tried CDK4/6 inhibitor therapy. It may help shrink tumors and improve outcomes for cancers that have come back or spread.
This trial tests a combination of an antibody-drug conjugate (ADC) and an immunotherapy drug (adebrelimab) for people with advanced HER2-negative breast cancer that has stopped responding to prior treatments. The goal is to see if this combination can help shrink or slow the cancer.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.